Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Solid Tumor × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 19 Brain Neoplasms 15 Central Nervous System Neoplasms 14 Astrocytoma 9 Glioma 7 Oligodendroglioma 5 Medulloblastoma 4 Neoplasms 3 Lymphoma 3 Gliosarcoma 3 Recurrence 2 Melanoma 2 Lymphoma, AIDS-Related 2 Leukemia, Myeloid, Acute 2 Uveal Melanoma 1 Spinal Cord Neoplasms 1 Solid Tumor 1 Optic Nerve Glioma 1 Neuroectodermal Tumors 1 Lung Neoplasms 1 Intraocular Lymphoma 1 Familial ependymoma 1 Ependymoma 1 Drug-Related Side Effects and Adverse Reactions 1 Cognition Disorders 1 Carcinoma, Non-Small-Cell Lung 1 Camurati-Engelmann Syndrome 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1

Interventions

senaparib 6 Irinotecan 6 pembrolizumab 5 Paclitaxel 5 Docetaxel 5 Cisplatin 5 Capecitabine 5 Fluorouracil 4 Rifampin 3 Midazolam 3 Leucovorin 3 Itraconazole 3 Injections 3 Bevacizumab 3 pertuzumab 2 atezolizumab 2 Nivolumab 2 Gemcitabine 2 vofatamab 1 tremelimumab 1 trastuzumab duocarmazine 1 talazoparib 1 sotorasib 1 saracatinib 1 ridaforolimus 1 regorafenib 1 prexasertib 1 pexidartinib 1 pemigatinib 1 pamiparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡